Literature DB >> 14755359

[A guideline for guidelines--methodological report and use of the guideline women's information].

U-S Albert1, K-D Schulz, D Alt, V Beck, J Doherty, K Holsteg, E Kalbheim, J Müller, I Nass-Griegoleit, J Nill, G Nioduschewski, H Schulte, A von Wietersheim, I Kopp.   

Abstract

UNLABELLED: Information and education is needed to empower autonomy and self-determination of patients (informed consent). Furthermore reliable and accurate medical information is necessary for patients who want to take an active part in medical decision-making. The aim of this work is to define the requirements helping to assure the development of good qualified information material relevant for women and female patients as "a guideline on women information". An example of its use is given by embeding this guideline in the guideline for early detection of breast cancer in Germany by defining the specific elements required for developing qualified information on this issue for women.
METHODS: A systematic, stepwise methodological process according to a level two guideline of the German Association of the Scientific Medical Societies (AWMF) and the Agency for Quality in Medicine (AZQ) was performed with the following elements: 1. Establishing an expert panel, 2. Generating the guideline statements by a formal, consensus based nominal group process, 3. External review process and finding supportive partners for the guideline on women information, 4. Using the guideline for guidelines: implementing the concept in the guideline of early detection of breast cancer in Germany.
RESULTS: The "guideline women information" comprises nine elements of quality assuring requirements for the development of gender-specific information material and eleven specific elements which directly relate to the guideline statements on early detection of breast cancer. After external review 30 organisations gave their written support for future implementation of the guideline. The "guideline women information" was integrated as a tool for quality assurance of lay information into the "guideline for early detection of breast cancer in Germany".
CONCLUSION: The "guideline women information" is a systematically developed, consensus-based recommendation to improve the development of qualified lay information at the point of its process by defining gender-specific aspects required for good lay information and its evaluation. As a guideline for guidelines its use is demonstrated by integrating this guideline into the "guideline for early detection of breast cancer in Germany" to ensure the development of qualified guideline compliant information.

Entities:  

Mesh:

Year:  2003        PMID: 14755359     DOI: 10.1055/s-2003-44816

Source DB:  PubMed          Journal:  Zentralbl Gynakol        ISSN: 0044-4197


  3 in total

1.  2008 update of the guideline: early detection of breast cancer in Germany.

Authors:  Ute-Susann Albert; Helmut Altland; Volker Duda; Jutta Engel; Max Geraedts; Syvia Heywang-Köbrunner; Dieter Hölzel; Eva Kalbheim; Michael Koller; Klaus König; Rolf Kreienberg; Thorsten Kühn; Annette Lebeau; Irmgard Nass-Griegoleit; Werner Schlake; Rita Schmutzler; Ingrid Schreer; Hilde Schulte; Rüdiger Schulz-Wendtland; Uwe Wagner; Ina Kopp
Journal:  J Cancer Res Clin Oncol       Date:  2008-07-26       Impact factor: 4.553

2.  Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: Short version - AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL - Kurzversion 3.0, Juli 2012.

Authors:  R Kreienberg; U-S Albert; M Follmann; I B Kopp; T Kühn; A Wöckel
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-06       Impact factor: 2.915

Review 3.  Short version of the Guideline: Early Detection of Breast Cancer in Germany. An evidence-, consensus-, and outcome-based guideline according to the German Association of the Scientific Medical Societies (AWMF) and the German Agency for Quality in Medicine (AeZQ).

Authors:  U-S Albert; K-D Schulz
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-18       Impact factor: 4.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.